30 results
8-K
EX-99.1
SCTL
Societal CDMO Inc
1 Apr 14
This presentation includes forward-looking statements within the meaning of Section
12:00am
properties
Not anxiolytic
Effective Analgesic
Dex Has Been Well Studied by Recro
Trial
Form
Design
Outcome
REC-11-010
Dex-IN
Chronic lower back
pain … -003
Dex-SL
Chronic lower back
pain POC study (n=21)
Statistically
significant reduction
in pain intensity demonstrated in
placebo controlled
8-K
EX-99.2
SCTL
Societal CDMO Inc
10 Nov 14
Recro Pharma Reports Third Quarter 2014 Financial Results
12:00am
intensity of 6 or below,
there was a trend towards analgesia in
50 mcg and reduced opioid use versus
placebo
REC-11-010
Dex-IN
Chronic lower back … -003
Dex-SL
Chronic lower back
pain POC study (n=21)
Statistically
significant reduction in pain
intensity demonstrated in placebo
controlled
8-K
EX-99.2
SCTL
Societal CDMO Inc
9 Sep 14
Recro Pharma to Present at the 2014 Aegis Healthcare & Technology Conference
12:00am
placebo
REC_11_010
Dex_IN
Chronic lower back
Statistically significant pain relief within
pain POC study (n=24)
30 minutes demonstrated … in placebo
controlled trial _ single use device
REC_09_003
Dex_SL
Chronic lower back
Statistically significant reduction in pain
pain POC study (n=21
8-K
EX-99.1
SCTL
Societal CDMO Inc
10 Aug 20
Recro Reports Second Quarter 2020 Financial Results
7:06am
the necessity of medications and treatment of chronic diseases. Given the continuing uncertainty of the potential impact of the pandemic on our business … of 2020 without loss of market share, we believe due to reduced total prescription (TRx) rates for many chronic therapeutics. Recro expects the COVID-19
8-K
EX-99.2
SCTL
Societal CDMO Inc
7 Nov 18
Recro Pharma Reports Third Quarter 2018 Financial Results
7:06am
monotherapy1
Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Post-operative Period In opioid-naive patients, many … surgical procedures are associated with an increased risk of chronic opioid use in the post-operative period1 6%-10% of opioid naïve surgical
8-K
EX-99.2
mjyzcn8h
1 Oct 18
Recro Announces Expansion of CDMO Service Capabilities
12:00am
8-K
EX-99.1
0tloh
7 Jan 19
Other Events
7:01am
8-K
EX-99.2
rvu3 8smjxqk9y7xqz4
19 Feb 19
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
7:05am
8-K
EX-99.1
1k92vqyn9w
10 May 18
Results of Operations and Financial Condition
7:03am
424B3
3mtm6b fj1
26 Feb 15
Prospectus supplement
12:00am
424B4
hvxlv0gn
7 Mar 14
Prospectus supplement with pricing info
12:00am
S-1/A
lyybn623oo8sz2lntyp
29 Nov 13
IPO registration (amended)
12:00am
10-K
nyuvxjdmot
25 Mar 15
Annual report
12:00am